Antimicrobial resistance of bacteraemia in the emergency department of a German university hospital (2013-2018): potential carbapenem-sparing empiric treatment options in light of the new EUCAST recommendations.
Kathrin RotheNina WantiaChristoph D SpinnerJochen SchneiderTobias LahmerBirgit WaschulzikRoland M SchmidDirk H BuschJuri KatchanovPublished in: BMC infectious diseases (2019)
Using an ureidopenicillin-beta-lactamase inhibitor combination at the high dose suggested by the new EUCAST recommendations provided nearly 93% coverage for relevant pathogens in patients with suspected bloodstream infection in our cohort. This might offer a safe option to reduce the empiric use of carbapenems. Our data support the absence of a general need for glycopeptides or oxazolidinones in empiric treatment.
Keyphrases
- antimicrobial resistance
- gram negative
- klebsiella pneumoniae
- emergency department
- high dose
- multidrug resistant
- urinary tract infection
- escherichia coli
- clinical practice
- acinetobacter baumannii
- low dose
- electronic health record
- big data
- drug resistant
- stem cell transplantation
- affordable care act
- machine learning
- robot assisted
- cystic fibrosis
- risk assessment
- adverse drug
- minimally invasive
- drug induced
- health insurance